Stockscreener 앱 받기
564.81
0.96%
-5.46
전일 마감가:
$570.27
열려 있는:
$565
하루 거래량:
830.76K
Relative Volume:
1.77
시가총액:
$24.75B
수익:
$3.18B
순이익/손실:
$1.33B
주가수익비율:
20.24
EPS:
27.9001
순현금흐름:
$1.04B
1주 성능:
+6.06%
1개월 성능:
+9.92%
6개월 성능:
+27.37%
1년 성능:
+80.88%
1일 변동 폭
$551.30
$577.86
1주일 범위
$520.97
$607.89
52주 변동 폭
$266.98
$607.89
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, ZTS, HLN, TEVA
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
564.81 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
TAK
Takeda Pharmaceutical Co Adr
|
18.74 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.94 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.93 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.08 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Underweight |
| 2025-09-26 | 개시 | RBC Capital Mkts | Outperform |
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,610,605.00 in Stock - MarketBeat
Allspring Global Investments Holdings LLC Has $52.05 Million Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics: Maintaining 'Strong Buy' On Second TETON Study Program Win (UTHR) - Seeking Alpha
United Therapeutics Corp at TD Cowen Healthcare Conference Transcript - gurufocus.com
United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
United Therapeutics (NASDAQ: UTHR) CFO exercises options and sells 10k shares - Stock Titan
UNITED THERAPEUTICS (UTHR) director exercises options and sells 1,300 shares under 10b5-1 plan - Stock Titan
UNITED THERAPEUTICS (UTHR) CEO sells 9,500 shares after option exercise - Stock Titan
Wells Fargo Raises Price Target for United Therapeutics (UTHR) t - gurufocus.com
United Therapeutics (NASDAQ:UTHR) Price Target Raised to $660.00 at HC Wainwright - MarketBeat
United Therapeutics (UTHR): Analyst Greg Harrison Raises Price T - gurufocus.com
United Therapeutics Gets Dual Target Hikes From BofA and Wells Fargo - 247wallst.com
Retirement Systems of Alabama Has $47.39 Million Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (UTHR) Moves 12.5% Higher: Will This Strength Last? - Yahoo Finance
United Therapeutics (UTHR) Achieves Key Milestone in IPF Treatme - gurufocus.com
United Therapeutics (UTHR) Sees Positive Results in TETON-1 Stud - gurufocus.com
United Therapeutics (UTHR) Tyvaso Shows Promising Results in TET - gurufocus.com
United Therapeutics stock surges 32% in 6 months: Here's why - MSN
United Therapeutics (UTHR) Stock Surges Over 12% - gurufocus.com
United Therapeutics (UTHR) Surges Nearly 12% - gurufocus.com
Why United Therapeutics (UTHR) Stock Is Up Today - Yahoo Finance
UTHR: TD Cowen Raises United Therapeutics Price Target to $660 | - gurufocus.com
United Therapeutics Announces Successful Tyvaso Trial - National Today
United Therapeutics (NASDAQ: UTHR) proposed sale of 1,300 shares via option - Stock Titan
United Therapeutics Stock Surges Due to Positive Phase 3 Trial Results - timothysykes.com
United Therapeutics Corp (UTHR) Stock Price Quote Today & Current Price Chart - Capital.com
United Therapeutics Rises on Positive Study for Cornerstone Drug. Why Shares Could Run Even Higher. - Barron's
U.S. Indexes Ended Monday Mixed As United Therapeutics Led, Sysco Lagged - Barron's
United Therapeutics Surges Amid Successful Phase 3 Trials - timothysykes.com
Ralinepag Clinical Trials Propel United Therapeutics Stock Soaring - stockstotrade.com
Stocks Rise As Powell's Remarks Cool Rate Fears: What's Moving Markets Monday? - Benzinga
United Therapeutics’ Nebulized Tyvaso Achieves Primary Endpoint in TETON-1 Study for Idiopathic Pulmonary Fibrosis, Outperforming Placebo and TETON-2 Results 12 - Minichart
United Therapeutics Corp (UTHR) Stock Price Up 13.08% on Mar 30 - GuruFocus
United’s Tyvaso nails endpoints in second phase III IPF trial - BioWorld MedTech
Jefferies raises United Therapeutics stock price target on IPF data By Investing.com - Investing.com India
BofA raises United Therapeutics stock price target on trial data By Investing.com - Investing.com Australia
BofA raises United Therapeutics stock price target on trial data - Investing.com
Jefferies raises United Therapeutics stock price target on trial data By Investing.com - Investing.com Australia
United Therapeutics shares surge after positive IPF trial results - Yahoo! Finance Canada
Jefferies raises United Therapeutics stock price target on IPF data - Investing.com
Jefferies raises United Therapeutics stock price target on trial data - Investing.com
United Therapeutics jumps 14.9% as investors refocus on big buyback and positive ralinepag Phase 3 readout - Quiver Quantitative
UNITED THERAPEUTICS CORPORATION (UTHR) - MSN
United Therapeutics (NASDAQ:UTHR) Shares Gap Up Following Analyst Upgrade - MarketBeat
United Therapeutics Tyvaso IPF Success Adds New Layer To Valuation Story - simplywall.st
Why Is United Therapeutics Stock Soaring Monday? - Benzinga
United Therapeutics (NASDAQ:UTHR) Stock Price Expected to Rise, TD Cowen Analyst Says - MarketBeat
TD Cowen raises United Therapeutics stock price target on trial win - in.investing.com
Morgan Stanley reiterates United Therapeutics stock rating on trial success By Investing.com - Investing.com India
Jefferies reiterates Buy on United Therapeutics stock after IPF trial By Investing.com - Investing.com South Africa
Morgan Stanley reiterates United Therapeutics stock rating on trial success - Investing.com
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
유나이티드 테라퓨틱스 주식 (UTHR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Apr 02 '26 |
Sale |
565.87 |
8,300 |
4,696,690 |
45,172 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Apr 01 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Apr 01 '26 |
Sale |
581.63 |
9,500 |
5,525,526 |
40,513 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 31 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 31 '26 |
Sale |
585.76 |
9,500 |
5,564,709 |
40,513 |
1.39%
자본화:
|
볼륨(24시간):